Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle programs. Among these is Sapu006, a polysorbate-free intravenous docetaxel formulation that is moving into Phase 1b clinical evaluation. Another program, Sapu003, is an intravenous everolimus nanomedicine currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform.
The announcement is significant because it addresses a key challenge in drug delivery: many potent therapeutics are highly water-insoluble, limiting their clinical use. The Deciparticle platform’s ability to form particles smaller than 20 nanometers could enable safer and more effective intravenous administration of such drugs. By improving the therapeutic index, these formulations may reduce side effects and enhance efficacy for cancer patients.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products targeting high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. In addition to its internal pipeline, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. The collaboration between Oncotelic and Sapu Nano underscores a shared commitment to advancing nanomedicine technologies that can transform cancer treatment.
For more information, the full press release is available at https://ibn.fm/RUG7m. Updates on Oncotelic Therapeutics can be found at https://ibn.fm/OTLC.
